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Abstract
An HIV vaccine capable of inducing high and durable levels of broadly neutralizing antibodies 
has thus far proven elusive. A promising antigen is the membrane-proximal external region 
(MPER) from gp41, a segment of the viral envelope recognized by a number of broadly 
neutralizing antibodies. Though an attractive vaccine target due to the linear nature of the epitope 
and its highly conserved sequence, MPER peptides are poorly immunogenic and may require 
display on membranes to achieve a physiological conformation matching the native virus. Here we 
systematically explored how the structure and composition of liposomes displaying MPER 
peptides impacts the strength and durability of humoral responses to this antigen as well as helper 
T-cell responses in mice. Administration of MPER peptides anchored to the surface of liposomes 
induced MPER-specific antibodies whereas MPER administered in oil-based emulsion adjuvants 
or alum did not, even when combined with Toll like receptor agonists. High-titer IgG responses to 
liposomal MPER required the inclusion of molecular adjuvants such as monophosphoryl lipid A. 
Anti-MPER humoral responses were further enhanced by incorporating high-Tm lipids in the 
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vesicle bilayer and optimizing the MPER density to a mean distance of ~10–15 nm between 
peptides on the liposomes' surfaces. Encapsulation of helper epitopes within the vesicles allowed 
efficient “intrastructural” T-cell help, which promoted IgG responses to MPER while minimizing 
competing B-cell responses against the helper sequence. These results define several key 
properties of liposome formulations that promote durable, high-titer antibody responses against 
MPER peptides, which will be a prerequisite for a successful MPER-targeting vaccine.
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1. Introduction
Development of a prophylactic HIV vaccine remains of critical importance for world health 
despite the many challenges facing this objective [1,2]. Based on studies in large animal 
models, induction of high and durable levels of broadly neutralizing antibody (BNAbs) 
should provide sterilizing immunity against HIV [3], although thus far, strategies to induce 
such antibodies by vaccination remain elusive [4]. The only proteins expressed on the 
surface of the HIV virion are the Env subunits gp120 and gp41, which form heterotrimeric 
spikes. The high mutation rate, low density of Env protein trimers on each viral particle, and 
the masking of highly conserved epitopes of the Env protein via glycosylation have all 
hindered efforts to develop an HIV vaccine [5,6].
The membrane proximal external region (MPER) of gp41 is a particularly attractive vaccine 
target because it is a highly conserved linear peptide to which a number of BNAbs (e.g., 
2F5, 4E10, 10E8 and Z13e1) bind [7–11]. One critical factor in MPER-targeting vaccine 
design is that this sequence comes just before the transmembrane region of gp41, and the 
conformation of the peptide is directly modulated by interaction with lipids. When 
associated with the surface of lipid micelles or membranes, MPER peptides form two 
hydrophobic helices connected by a flexible hinge region, and this unique conformation of 
membrane-displayed MPER substantially influences its binding to 2F5 and 4E10 [12–14]. 
These findings have motivated strategies aiming to present MPER sequences in a defined 
helical structure [15,16]. For example, gp41 peptides have been incorporated as constrained 
epitopes within protein scaffolds [17–21] or displayed on virus-like particles (VLPs) [22] 
and although some formulations have been weakly immunogenic [23], other constructs have 
been able to produce 2F5-like antibodies with some neutralizing and ADCC activity after 
multiple booster immunizations [24].
Scaffolded epitopes can present a defined configuration but lack the surrounding lipid 
environment of the native MPER which may impact elicitation of BNAbs with 2F5 or 4E10-
like characteristics. Thus, a second approach to promote a native conformation of gp41 
epitopes has been to display MPER peptides on lipid vesicles. Although MPER peptides are 
weakly immunogenic, liposomal vaccine formulations have generated antibody responses 
[25] which can be enhanced via multiple booster immunizations [26,27], administration with 
complete Freund’s adjuvant [28], or through optimizing anchorage of lipid-conjugated 
MPER molecules in the lipid membrane [29,30].
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Considering the requirements of presenting MPER in a conformation-mimicking display on 
the virus and the need to enhance MPER immunogenicity, liposomal delivery of structure-
guided peptide antigens is a particularly attractive vaccination strategy. The presentation of 
antigen in a nanoparticulate form increases lymphatic uptake, slows antigen clearance from 
lymph nodes, increases antigen capture by antigen presenting cells, and promotes B-cell 
receptor crosslinking [31,32]. Hydrophilic adjuvant compounds can be encapsulated in the 
interior of liposomes or anchored to the bilayer, while hydrophobic compounds can be 
embedded in the lipid bilayer. We recently reported that MPER anchored into a lipid 
membrane via a palmitoyl tail binds 2F5 and 4E10 and is more immunogenic than 
unmodified MPER absorbed onto lipid membrane surfaces [29], consistent with the findings 
of Watson et al. [30]. Here we evaluated the role of 3 key properties modulating the 
immunogenicity of MPER liposomal vaccines: liposome composition and size, inclusion of 
molecular adjuvants, and incorporation of intrastructural (within the same liposome) T-cell 
help.
2. Material and methods
2.1. Materials
Lipids 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phoshpo-(1′-rac-gylcerol) (DOPG), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(DSPE-PEG), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[PDP(polyethylene 
glycol)-2000] (DSPE-PEG-PDP) were purchased from Avanti Polar Lipids (Alabaster, AL). 
Solvents, bovine serum albumin (BSA) and monophosphoryl lipid A (MPLA, from 
Salmonella enterica serotype minnesota Re 595 cat. no. L6895) were purchased from Sigma 
Aldrich (St. Louis, MO). Ovalbumin (OVA) was purchased from Worthington Biochemical 
(Lakewood, NJ) and purified via detoxi-gel endotoxin removal columns (Pierce 
Biotechnology, Rockford, IL). Montanide ISA 51 VG was purchased from Seppic (Puteaux, 
France). AddaVax and cylic-di-GMP were purchased from Invivogen (San Diego, CA). 
Lipo-S-S-(PEG)4-CpG (Lipid-PEG-CpG) was synthesized as previously described [33]. 
Briefly, CpG 1826 was synthesized using an ABI 394 DNA synthesizer (Applied 
Biosystems, Carlsbad, CA) on a 1.0 micromole scale, 5′ coupled to 4 repeats of DMT-
hexaethyloxy-glycol phosphoramidite (Chemgenes, Wilmington, MA), thiol modifier C6 S-
S (Glenres, Sterling, VA), and finally conjugated with lipid phosphoramidite (diacyl lipid 
phosphoramidite, synthesized according to published procedure [33]). After synthesis, lipid-
PEG-CpG was purified by reverse phase HPLC. The CD4+ T helper peptides LACK1 
(ICFSPSLEHPIVVSGSWD) and HIV30 (RRNIIGDIRQAHCNISRAKW) and MPER 
peptide (ELDKWASLWNWFNITNWLWYIK) were synthesized at the Tufts University 
Core Facility (Boston, MA). MPER was purchased with either an N-terminal biotin (for 
ELISAs) or palmitoyl tail (for immunizations). For membrane-anchored DSPE-HIV30 
conjugates, HIV30 was linked to DSPE-PEG-PDP via the cysteine residue of HIV30, by 
dissolving the peptide in DMF with 1.5 equivalents of DSPE-PEG-PDP and agitating at 
25°C for 18 hours. The conjugate was then diluted in 10× deionized water, lyophilized into 
powder, and redissolved in deionized water. Peptide concentrations were determined by 
Direct Detect infrared spectroscopy analysis (EMD Millipore, Billerica, MA).
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2.2. Liposome synthesis and characterization
A 4:1 molar ratio of DOPC:DOPG (for DOPC liposomes) or a 2:2:1 molar ratio of 
DMPC:DOPC:DOPG (for DMPC liposomes) in chloroform with or without 10 mol% of 
DSPE-PEG and palm-MPER added at a 1:200 MPER:lipid mole ratio was dried under 
nitrogen followed by incubation under vacuum at 25°C for 18 hr. Liposomes incorporating 
lipid-PEG-CpG, MPLA, or DSPE-HIV30 were prepared by including these components in 
the organic solution prior to drying lipid films. Lipids were hydrated with pH 7.4 PBS 
(containing 1 mg/mL LACK1 or 0.2 mg/mL HIV30 for soluble delivery of T-helper peptide) 
to a final concentration of 26.5 mM lipid and vortexed 30 seconds every 10 minutes for an 
hour. For 150 and 200 nm diameter liposomes, the resulting vesicles were passed through 
six freeze-thaw cycles between liquid nitrogen and a 37°C water bath followed by extrusion 
21 times through 0.2μm or 0.4μm pore polycarbonate membranes (Whatman Inc, Sanford, 
ME), respectively. For 65 nm diameter liposomes, the lipid resuspension was subjected to 5 
minutes of sonication alternating for 30 second periods between 10 watts and 3 watts output 
power on a Misonix XL-2000 probe sonicator. Efficiency of pMPER loading was 
determined by measuring fluorescence signal of liposomes loaded with a FITC-labeled 
pMPER before and after centrifugation via Airfuge (Beckman-Coulter). For c-di-GMP 
liposomes, a 38:38:19:5:0.95 molar ratio of DMPC:DOPC:DOPG:DSPE-PEG:c-di-GMP in 
chloroform was dried under nitrogen followed by incubation under vacuum at 25°C for 18 
hr and following drying, the resulting lipid/c-di-GMP films were resuspended at 240 μg/mL 
of c-di-GMP in PBS and then freeze/thawed and extruded to form 150 nm liposomes. 
Unencapsulated c-di-GMP was removed by centrifugation of the liposomes via Airfuge 
(Beckman-Coulter) and quantification of c-di-GMP encapsulation efficiency was 
determined by UV absorption at 254 nm. Cryoelectron microscopy (Jeol 2100F TEM) and 
dynamic light scattering (Wyatt Dyna Pro Plate Reader II) were performed by the Swanson 
Biotechnology Center at the Koch Institute. For the calculation of the number of MPER 
peptides per liposomes, we utilized the following equation for the number of lipids (NTotal) 
per liposome, where a = surface area of a single phospholipid headgroup, h = bilayer width, 
and d = liposome diameter:
2.3. Mice and immunization protocol
Female BALB/c mice 6–7 weeks of age were purchased from Jackson Laboratories for all 
immunizations, and handled under federal, state, and local guidelines. Mice were immunized 
by injection of 100 μL MPER liposome solutions (40 μg MPER peptide) s.c. at the tail base, 
50 μL on each flank, and boosted on days 21 and 42 with the same formulations. Where 
indicated, MPER liposomes included 17.5 μg MPLA or lipid-PEG-CpG as adjuvant. 
Alternatively, 100 uL cdGMP liposomes (5 μg cdGMP) were administered s.c. at the tail 
base, 50 uL per side, directly following MPER liposome injection. T-cell help was 
incorporated as 100 μg LACK1 peptide or 20 μg HIV30 peptide as indicated. Serum was 
collected weekly via retro-orbital bleeding for subsequent ELISA-based titer analyses. For 
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CD4+ T-cell depletion studies, mice were injected i.p. with 0.3 mg anti-CD4 antibody 
(GK1.5, BioXCell) three days prior to, and 3 and 9 days after each immunization.
2.4. Immune responses analyses
For T-cell responses, mice were euthanized and 300,000 splenocytes in single cell 
suspensions were seeded into 96-well plates with or without 5 μM HIV30 peptide. Cells 
were incubated for 48 hours, and supernatants were collected for cytokine analysis using a 
Milliplex MAP mouse Th17 Magnetic Bead Kit from EMD Millipore (Billerica, MA) and 
the Bio-Plex 3D suspension array system from Bio-Rad (Hercules, CA). MPER-specific 
antibody levels were detected by ELISA: 96-well Nunc Polysorp plates (ThermoFisher) 
were coated with 25 μg/mL streptavidin (Jackson ImmunoResearch, West Grove, PA), 
blocked with 1% w/v BSA in PBS (BSA-PBS), washed with 0.05 Tween 20 in PBS, and 
incubated for 2 hours with 2 μg/mL biotin-MPER in BSA-PBS, washed, and then incubated 
for 2 hours with serially diluted serum samples. Following another washing step, the plates 
were incubated for 90 minutes with HRP-conjugated goat anti-mouse IgG (Bio-Rad) or anti-
mouse IgM (Abcam) in BSA-PBS, washed, developed with TMB substrate, and read on a 
Tecan Infinite M200 Pro (Männedorf, Switzerland) absorbance plate reader. HIV30-specific 
antibody levels were detected via ELISA in a similar manner; plates were directly coated 
with 100 μg/mL of HIV30, blocked, washed, and incubated with serum and IgG-HRP as 
described above. Titers were defined as the inverse serum dilution giving an absorbance of 
0.3. Frequencies of germinal center (GC) cells in inguinal and axillary lymph nodes were 
determined by flow cytometry analysis using a FACS Canto II (BD Biosciences) following 
staining with markers for GC cells (anti-B220, anti-GL-7, anti-IgD, peanut agglutinin (PNA) 
as well as 4′,6-diamidino-2-phenylindole (DAPI, for live-dead analysis). Data were analyzed 
using FlowJo software (TreeStar, Oregon, USA).
2.5 Histology
Inguinal lymph nodes were isolated from immunized mice and frozen in Tissue-Tek O.C.T. 
Compound (Sakura Finetek, Torrance, CA). 10 μm tissue sections were prepared by the 
Swanson Biotechnology Center at the Koch Institute, and imaged on a Zeiss LSM 510 
confocal laser scanning microscope.
2.6 Statistics
Statistical analyses were performed using GraphPad Prism software. Comparisons of 
formulations over time employed two-way ANOVA tests and comparisons of multiple 
formulations at a single time point were performed using one-way ANOVA and Tukey’s 
tests. Two-tailed unpaired t-tests were used to determine statistical significance between two 
experimental groups for all other data unless otherwise noted.
3. Results & Discussion
3.1. MPER delivered on liposomes is immunogenic while traditional aluminum- or oil-
based adjuvants elicit no response to MPER peptides
We first compared several candidate lipophilic formulations as potential adjuvants for 
MPER peptides. Liposomes incorporating palmitoylated MPER (pMPER) were prepared by 
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lipid rehydration and extrusion; the hydrophobic pMPER was incorporated into PEGylated 
and non-PEGylated liposomes with efficiencies of 95±2.3% and 94±4.8%, respectively. 
Cryoelectron microscopy imaging of 150 nm diam. liposomes revealed the presence of 
unilamellar and multilamellar vesicles and incorporation of pMPER had no impact on 
liposome structure (Fig. 1A). In addition to liposomes, water/oil emulsions are classical 
adjuvants [34], which could potentially adsorb the hydrophobic pMPER to promote uptake 
by immune cells. We thus compared the immunogenicity of pMPER carried by liposomes, 
an oil-in-water emulsion (AddaVax), or a water-in-oil emulsion (Montanide), and also 
compared to the traditional adjuvant alum. To provide further adjuvant activity, the TLR-4 
agonist monophosphoryl lipid A (MPLA) was added to all of the formulations (liposomes, 
AddaVax, and Montanide) in this experiment as a molecular adjuvant [35]. Strikingly, even 
in the presence of MPLA, only liposomes primed anti-MPER IgG responses in all animals 
(Fig. 1B). Immunization with liposomes carrying lipid-anchored MPER and helper peptide 
without additional molecular adjuvants elicited a detectable but very weak immune 
response, but MPER liposomes adjuvanted with several different molecular danger signals–
MPLA, lipid-PEG-CpG, or co-administered liposomes containing the STING agonist cyclic-
di-GMP (cdGMP) [36–38]–all primed 600–4600-fold higher anti-MPER titers (Fig. 1C). 
Note that to separately control the MPER and cdGMP doses it was necessary to co-deliver 
cdGMP in separate liposomes. Based on these data showing equivalence of MPLA and CpG 
and elevated responses elicited by the cyclic dinculeotides, we opted to focus on MPLA (as 
representative of an agonist already used in licensed vaccines) and cdGMP (encapsulated in 
separate liposomes) as adjuvants for further studies. Antibody responses raised by these 
MPER liposome vaccines supplemented with helper peptides appeared to be classically T-
help-dependent, as IgG titers following immunization were reduced by >90% in CD4+ T-
cell-depleted animals (Supplementary Fig. 1).
3.2. Magnitude of MPER-specific antibody responses is controlled by liposome physical 
properties
Poly(ethylene glycol) (PEG) coatings are routinely used in drug delivery to limit liposome 
aggregation/fusion and enhance their penetration through tissue [39], and thus might 
promote trafficking of MPER liposomes to draining lymph nodes. However, because the 
MPER sequence embeds into the lipid membrane, PEGylation of MPER liposomes would 
also be expected to hinder antigen-specific B-cell engagement with the peptide. PEGylation 
has variously been reported to facilitate draining to lymph nodes [40] as well as to have no 
impact on lymph node draining [41]. We found that four hours after immunization with 
liposomes co-labeled with the lipid dye DiD and encapsulated AlexaFluor-conjugated 
ovalbumin (AF-OVA), both PEGylated and non-PEGylated liposomes were readily detected 
in both the primary (inguinal) and secondary (axillary) draining lymph nodes via IVIS-based 
fluorescent imaging of whole lymph nodes and confocal microscopy of histological lymph 
node sections (Fig. 2A–B). DiD (green) and AF-OVA (red) signals were co-localized in the 
subcapsular sinus of inguinal lymph nodes, suggesting that liposomes were still intact four 
hours post-immunization (Fig. 2A). Quantification of AF-OVA signal detected from whole 
lymph nodes via IVIS indicated that PEGylated liposomes trended toward increased 
accumulation in lymph nodes relative to non-PEGylated vesicles, but this did not reach 
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statistical significance (Fig. 2B). However, this slight enhancement of vesicle trafficking 
achieved by PEGylation had no impact on immunogenicity (Fig. 2C).
Particle size plays a key role in vaccine responses, though optimal dimensions are likely 
dependent on particle composition and the type of immune responses desired [42]. In 
parallel to the liposome draining analyses, vesicles with mean diameters of 203±27 nm, 
150±12 nm, or 64.5±5 nm were tested as MPER/MPLA delivery vehicles. Interestingly, 
immunization with the smallest 65 nm liposomes induced 20-fold and 15-fold lower MPER-
specific IgG titers than 150 nm and 200 nm liposomes, respectively (Fig. 2D). This inverse 
relationship between immunogenicity and liposome size is in agreement with prior studies 
of flexible liposomes in the size range of 40 – 400 nm, where vesicle size was inversely 
correlated with drainage from the injection site but positively correlated with retention in 
draining lymph nodes [43].
The immunogenicity of protein or hapten antigens delivered by liposomes has been shown 
previously to be inversely proportional to membrane fluidity [44–46], and we expected a 
similar trend due to more stable anchoring of pMPER to vesicles with more rigid bilayers. In 
agreement with these predictions, immunization of mice with low-fluidity 2:2:1 
DMPC:DOPC:DOPG liposomes (Average Tm = 6.7°C) or fully-fluid 4:1 DOPC:DOPG 
liposomes (Average Tm = −8.1C) showed that DMPC-containing vesicles elicited an 
average 6.2-fold higher titer than DOPC-only liposomes (Fig. 2E). We sought to test 
liposome compositions with higher mean melting temperatures, but found that pMPER 
peptides were unstable in lipid membranes with melting temperatures above 37°C (data not 
shown).
3.3. Humoral responses are maximized by high-density MPER display on vesicles
Multivalent surface-display of antigen on particulates is known to enhance antibody 
responses, presumably by promoting BCR aggregation [47,48]. To understand how the 
surface density of antigen impacts pMPER immunogenicity, we immunized mice with a 
fixed total dose of antigen delivered on liposomes carrying varying quantities of pMPER per 
liposome. Serum antibody titers post-boosting indicated that 200 pMPER per liposome 
initially generated the highest MPER-specific IgG levels, but densities ranging from 40 to 
1000 pMPER per liposome were all capable of generating high titers by day 50 (Fig. 3A). 
Interestingly, the highest antigen density tested, 2000 MPER/liposome, elicited substantially 
lower titers, suggesting that the optimal mean distance between peptides on the liposome 
surface is approximately 7 – 17 nm (Fig. 3B).
3.4. Immunization with soluble or lipid-anchored T-helper peptide reduces off-target 
antibody responses
Preliminary studies suggested that exogenous helper epitopes enhanced the humoral 
response against MPER peptides in balb/c mice [29], and thus our immunizations included 
either the model H-2d-restricted LACK1 helper peptide (derived from Leishmania [49]) or 
HIV30, a gp120-derived peptide known to be presented by both H-2d in balb/c mice and 
HLAs of humans [50]. In order to maximize CD4+ T-cell help through co-delivery of MPER 
and helper epitopes to B-cells while avoiding off-target antibody responses against the 
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helper peptide, we tested three different methods for incorporating helper peptides into 
liposomes (Fig. 4A): Palmitoylated HIV30 anchored to the lipid bilayer (“palm HIV30”); 
HIV30 anchored through a disulfide linkage to a PEG tether on the bilayer (“uncleaved 
HIV30”); or disulfide/PEG-linked HIV30 cleaved from the external surfaces of the vesicles, 
leaving it incorporated only on the interior of the liposomes (“cleaved HIV30”). The latter 
formulations were obtained by exposing uncleaved HIV30 liposomes to the membrane-
impermeable reducing agent TCEP, followed by removal of free peptide. We first compared 
the T-cell priming capacity of these 3 modes of intrastructural HIV30 co-delivery, vs. 
soluble HIV30 mixed with liposomes. Splenocytes from animals immunized with all 3 
forms of MPER/HIV30 liposomes and restimulated ex vivo with HIV30 peptide secreted 
IL-4 (Fig. 4B) and IL-5 (Fig. 4C), but liposomes containing PEG-anchored HIV30 (cleaved 
or uncleaved) generated stronger TNF-α responses(Fig. 4D). Minimal T-cell responses were 
detectable against the MPER peptide itself (data not shown).
We next confirmed that HIV30 could enhance antibody responses to MPER, using the 
cleaved HIV30 form to co-incorporate the helper peptide into MPER liposomes. As shown 
in Fig. 5A, induction of anti-MPER IgG following immunization with MPER liposomes 
adjuvanted by co-delivered cdGMP liposomes was dependent on the presence of HIV30, 
confirming importance of the T-helper epitope. To compare the relative effectiveness of the 
3 modes of helper epitope incorporation, mice were immunized with pMPER liposomes 
containing palm HIV30, uncleaved HIV30, cleaved HIV30, or pMPER liposomes co-
administered with unencapsulated soluble HIV30; each vaccine was adjuvanted with 
cdGMP liposomes. While all 4 formulations elicited strong anti-MPER titers at 7 days post-
boost, soluble HIV30 and cleaved HIV30 minimized off-target anti-HIV30 IgG titers (Fig. 
5B). Flow cytometry-based assessment of germinal center B cell populations at 7 days post-
boost indicated that all 4 formulations primed substantial germinal center B-cell populations 
(Fig. 5C). These results suggest that cleaved HIV30 offers the optimal balance between 
strong humoral MPER-specific responses, weak off-target antibody generation and strong 
induction of Th1- and Th2-associated cytokines.
4. Conclusions
MPER is a highly hydrophobic sequence near the transmembrane domain of gp41, which 
exhibits substantially enhanced immunogenicity when displayed on the surface of 
liposomes. In order to design a potent MPER vaccine, we systematically optimized three 
critical elements of a liposomal MPER vaccine: liposome properties, adjuvant incorporation, 
and T-cell help. The present studies demonstrate that humoral responses to liposomal MPER 
vaccines are impacted by all three of these components. Importantly, anti-MPER antibody 
responses are potently adjuvanted by the inclusion of TLR-4, TLR-9, or STING agonists, 
and are maximized by incorporation of high surface densities of MPER and the inclusion of 
high melting temperature lipids. The data suggest that 150 nm diameter, 2:2:1 
DMPC:DOPC:DOPG liposomes adjuvanted with MPLA or cdGMP and incorporating 
encapsulated T-cell helper epitopes achieve strong and durable antibody responses against 
gp41 MPER peptides, while limiting competing humoral responses against the helper 
sequence itself. Our studies of the biochemistry of antigen recognition carried out in parallel 
to the formulation studies described here showed that the MPER peptides tested here do not 
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elicit neutralizing antibodies against HIV [29]. Epitope mapping suggested this is due to an 
immunodominant response to residues at the free end of the peptides, which preliminary 
data suggests can be alleviated by incorporation of transmembrane segments of gp41 [29]; 
ongoing studies are testing such structures. Irrespective of these immunogen structure issues, 
the results reported here provide a clear guide to enhancing the immunogenicity of these and 
other novel MPER constructs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Humoral responses against MPER peptides are promoted by liposomal delivery and 
molecular adjuvants. (A) Representative cryoelectron microscopy images of 150 nm mean 
diameter DOPC/DOPG liposomes with or without incorporated pMPER, scale bars 100 nm. 
(B–C) Groups of balb/c mice (n=3–4/group) were immunized on days 0, 21, and 42 with 40 
μg pMPER peptide. (B) Anti-MPER serum IgG titers following immunization with pMPER 
delivered by liposomes, alum, or oil-based emulsions together with 100 μg soluble LACK1 
helper peptide and 17.5 μg MPLA per injection. (C) Serum anti-MPER IgG titers following 
immunization with pMPER on 150 nm diameter liposomes adjuvanted with MPLA, lipid-
PEG-CpG, or co-delivered cyclic-di-GMP (cdGMP) liposomes. To provide CD4+ T-cell 
help, formulations contained 20 μg of encapsulated HIV30. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001 as determined by ANOVA followed by Tukey’s multiple comparison test.
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Fig. 2. 
Anti-MPER humoral responses are shaped by liposome composition and particle size. (A–
B) Balb/c mice (n=3/group) were injected with 150 nm diameter pMPER liposomes with or 
without 10 mol% PEG-DSPE containing DiD lipid and OVA-AlexaFlour-555, followed by 
histological sectioning (red = OVA-AF555, green = DiD, 10× magnification, scale bar = 200 
μm) of inguinal nodes (A) and IVIS-based fluorescence quantification of axillary and 
inguinal nodes at 4 hours post-immunization (B). *, p < 0.05; **, p < 0.01 as determined by 
Dunnett’s test. (C) Anti-MPER titers at day 49 for balb/c mice (n=3/group) immunized as in 
(A) with pMPER/MPLA liposomes and LACK1 helper peptide on days 0, 21, and 42. (D) 
Serum anti-MPER IgG titers at one week after the third immunization in mice immunized 
with 65, 150 or 200 nm diameter PEGylated pMPER /MPLA liposomes and LACK1 helper 
peptide (** = p value < .01). (E) Mice were immunized as in (D) with 150 nm diameter 
PEGylated liposomes with a bilayer composition comprised of 4:1 DOPC:DOPG lipids or 
2:2:1 DMPC:DOPC:DOPG lipids and serum MPER titers were followed over time; p < 
0.0001 by two-way ANOVA.
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Fig. 3. 
Anti-MPER humoral responses are maximized by liposomes carrying peptide with a mean 
spacing near 10 nm. Groups of balb/c mice (n=4/group) were immunized with PEGylated 
MPER/MPLA liposomes bearing 20–2000 peptides per vesicle on average, mixed with 
LACK1 helper peptide. (A) Dependence of serum anti-MPER IgG titers on the density of 
antigen per liposome. (B) Correlation of serum anti-MPER IgG titer and the mean distance 
between pMPER antigens on the liposome surfaces. *, p < 0.05 as determined by ANOVA 
followed by Tukey’s multiple comparison test.
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Fig. 4. 
Liposomes carrying encapsulated bilayer-anchored helper peptide stimulate both Th1 and 
Th2 cytokine production from antigen-specific T-cells. (A) Schematic of 3 forms of T-
helper epitope incorporation in MPER liposomes. (B–D) Groups of balb/c mice (n=3/group) 
were immunized as in Fig. 1 with 150 nm diameter pMPER liposomes containing the T-
helper peptide HIV30 either in soluble form or incorporated into the MPER liposomes via a 
palmitoyl anchor or DSPE-PEG-S-S-HIV30 (cleaved or uncleaved) and all groups were 
adjuvanted by mixing with cdGMP liposomes. On day 49, splenocytes were isolated and 
restimulated ex vivo for 48 hours in the presence of 5 μM HIV30 peptide and concentrations 
of (B) IL-4, (C) IL-5, and (D) TNF-α, were determined via bead-based ELISA. *, p < 0.05; 
**, p < 0.01; ***, p < 0.001 for HIV30 vs. media only restimulation conditions as 
determined by two-way ANOVA and Bonferonni post-test.
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Fig. 5. 
Liposomes with surface-displayed pMPER and encapsulated HIV30 promote strong B-cell 
responses against MPER while minimizing off-target responses against the helper epitope. 
(A) Balb/c mice (n=5/group) were immunized with cdGMP liposomes mixed with 150 nm 
diam. pMPER liposomes with or without cleaved DSPE-PEG-S-S-HIV30 helper epitope on 
days 0 and 21, and serum IgG titers were measured on day 28. ***, p value < 0.001 (B–C) 
Balb/c mice (n=3–4/group) were immunized as in Fig. 1 with 150nm MPER liposomes 
containing the T-helper peptide HIV30 either in soluble form or incorporated into the MPER 
liposomes via a palmitoyl anchor or DSPE-PEG-S-S-HIV30 (cleaved or uncleaved); all 
groups were adjuvanted with co-delivered cdGMP liposomes. Shown are serum anti-MPER 
and anti-HIV30 IgG titers at seven days post-boost 1 (B) and frequencies of germinal center 
B-cells in draining lymph nodes at 7 days post-boost 2 (C). *, p < 0.05; **, p < 0.01 as 
determined by Dunnett’s comparison to control test.
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